在败血症引起的免疫抑制中,通过miR-223调节FOXO1介导的自
Guoan Xiang1,2, Qi Li3, Di Lian1
1College of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, Beijing, China.
Frontiers in pharmacology
|October 23, 2024
概括
微RNA-223 (miR-223) 通过控制FOXO1表达,在败血症期间调节CD4+T细胞的自. 这一发现为败血症诊断和治疗策略提供了新的见解.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
- 分子医学是分子医学.
背景情况:
- 败血症导致免疫抑制,其特征是CD4+ T淋巴细胞功能降低,影响患者的预后.
- 自在毒症中观察到的免疫失调中发挥着关键作用.
研究的目的:
- 研究微RNA-223 (miR-223) 在毒症期间在CD4+ T淋巴细胞内调节自的作用.
- 在败血症的背景下,阐明将miR-223,FOXO1和自连接在一起的分子机制.
主要方法:
- 已建立的细胞模型与miR-223的过度表达和CD4+T淋巴细胞的敲击.
- 使用mRFP-GFP-LC3晶体病毒和电子显微镜来监测自水平.
- 采用西部斑点分析来评估与自相关的蛋白质和FOXO1表达在脂多糖 (LPS) 和siRNA治疗后.
主要成果:
- 增加的miR-223表达与减少的FOXO1和减少的自相关.
- 抑制FOXO1显著降低了LPS诱导的CD4+T细胞的自.
- miR-223通过FOXO1调节在CD4+T淋巴细胞中直接影响LPS诱导的自.
结论:
- miR-223是发生败血症时CD4+T淋巴细胞自的关键调节剂,通过FOXO1通路起作用.
- 这项研究为败血症的潜在治疗干预提供了一个新的分子标.
相关概念视频
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K


